title: Relationship between matrix metalloproteinase-2 mRNA expression and clinicopathological and urokinase-type plasminogen activator system parameters and prognosis in human gastric cancer.
abstract: OBJECTIVE
  To investigate the relationship between matrix metalloproteinase-2 (MMP-2) mRNA expression and clinicopathologic and urokinase-type plasminogen activator (uPA) system parameter and prognosis in human gastric cancer.
  
  
  METHODS
  Expression of MMP-2 mRNA, uPA, and uPA-R mRNA in tumor tissues and > or =5 cm adjacent normal tissues from 67 cases of gastric cancer was studied using RT-PCR and Northern blot respectively. Survival analyses were done using the Kaplan-Meier method.
  
  
  RESULTS
  The expression rates of MMP-2 mRNA, uPA and uPA-R mRNA in tumor tissues (31%, 41%, and 51%, respectively) were significantly higher than those in > or =5 cm adjacent tissues (19%, 11%, and 9%; chi(2) = 4.59, 43.58, and 53.24 respectively, P<0.05, 0.0001, and 0.0001, respectively). Expression of MMP-2 mRNA was significantly correlated with lymph node metastasis (metastasis: 61.9%, no metastasis: 39.1%, chi(2) = 7.61, P<0.05), Lauren's classification of diffuse/mixed types: 54.2%, intestinal type: 26.3%, chi(2) = 4.25, P<0.05, expression of uPA and uPA-R mRNA (uPA+: 55.1%, uPA-: 22.2% and uPA-R+: 54.9%, uPA-R-: 18.8%, chi(2) = 5.72 and 6.40 respectively, P<0.05). Kaplan-Meier survival analysis of MMP-2 mRNA expression did not show significant difference in all 67 cases, but revealed an association of the expression of MMP-2 mRNA, uPA, and uPA-R mRNA with worse prognosis (P = 0.0083, 0.0160, and 0.0094, respectively).
  
  
  CONCLUSIONS
  MMP-2 may play an important role in the development of invasion and metastasis of gastric cancer.
authors.affiliation: Department of Gastroenterology, First Affiliated Hospital of Medical College, Zhejiang University, Qingchun Road 79, Hangzhou 310003, Zhejiang Province, China. jifeng1126@sina.com.cn
authors.forename: Feng
authors.initials: F
authors.lastname: Ji
authors.forename: Yue-Liang
authors.initials: YL
authors.lastname: Chen
authors.forename: En-Yun
authors.initials: EY
authors.lastname: Jin
authors.forename: Wei-Lin
authors.initials: WL
authors.lastname: Wang
authors.forename: Zi-Li
authors.initials: ZL
authors.lastname: Yang
authors.forename: You-Ming
authors.initials: YM
authors.lastname: Li
mesh_terms: D000328:Adult; D000368:Aged; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D008207:Lymphatic Metastasis; D008297:Male; D020778:Matrix Metalloproteinase 2 / Q000235:genetics*; D008875:Middle Aged; D011379:Prognosis; D012333:RNA, Messenger / Q000032:analysis; D011956:Receptors, Cell Surface / Q000235:genetics*; D055293:Receptors, Urokinase Plasminogen Activator; D013274:Stomach Neoplasms / Q000235:genetics* / Q000401:mortality / Q000556:secondary; D014568:Urokinase-Type Plasminogen Activator / Q000235:genetics*
chemical_list: C524898:PLAUR protein, human; D012333:RNA, Messenger; D011956:Receptors, Cell Surface; D055293:Receptors, Urokinase Plasminogen Activator; D014568:Urokinase-Type Plasminogen Activator; D020778:Matrix Metalloproteinase 2